Category: InVivo Therapeutics Corp.Syndicate content

InVivo Therapeutics looks to raise $12m for spine trial

February 2, 2015 by Mark Hollmer

Massachusetts-based InVivo Therapeutics looks to raise $12 million in a direct offering as it enrolls the 2nd patient in a feasibility trial for its neuro-spinal scaffold.

InVivo Therapeutics looks to raise $12 for spine trial

InVivo cleared to advance spinal injury study

January 14, 2015 by Val Kennedy

InVivo Therapeutics gets a green light to reopen enrollment in a clinical study of its neuro-spinal scaffold for treating acute spinal cord injuries.

InVivo cleared to advance spinal injury study

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA OKs expedited enrollment for InVivo study

December 18, 2014 by Val Kennedy

The FDA approves an expedited enrollment plan for a 5-patient pivotal study testing InVivo Therapeutics' neuro-spinal scaffold devices in the treatment of severe spinal cord injuries.

FDA OKs expedited enrollment for InVivo study

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Shares soar for InVivo after spinal cord study update | Medtech Wall Street news for the week of November 17, 2014

November 20, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo shares soar on spinal cord study update; Actavis trumps Valeant with $66B offer for Allergan; Medtronic's Q2 results meet The Street; Venture capital investment in medtech grows in Q3

InVivo shares soar on spinal cord study update

November 13, 2014 by Val Kennedy

InVivo shares soar on spinal cord study update

November 13, 2014 by Val Kennedy

InVivo Therapeutics shares soar after Arizona doctors confirm they have treated the first patient in a study for the company's experimental bio-scaffolding device for acute spinal-cord injuries.

InVivo shares soar on spinal cord study update

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Second suitor cedes the field early to Zimmer | Medtech Wall Street news for the week of September 15, 2014

September 18, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Second suitor ceded early to Zimmer in chase for Biomet; Kimberly-Clark readies Halyard Health medical device spinout; InVivo's stock drops as ex-CEO dumps shares; Mevion Medical files for $69M IPO; ReWalk Robotics prices IPO at $36M, below range

Second suitor ceded early to Zimmer in chase for Biomet

September 12, 2014 by Brad Perriello

InVivo's stock drops as ex-CEO dumps shares

September 11, 2014 by Arezu Sarvestani

InVivo Therapeutics ex-CEO Frank Reynolds has been liquidating his position in the company, putting even more weight on NVIV's already-pressured shares.

InVivo's stock drops as ex-CEO dumps shares

As if InVivo Therapeutics (OTC:NVIV) wasn't having a tough enough time already, the company's stock is under even more pressure as former CEO Frank Reynolds has been liquidating his position over the last few weeks.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.